{"entity":{"id":"nrg-br002","kind":"trial","name":"NRG-BR002: metastasis-directed ablation in limited metastatic breast cancer","aka":["NRG BR002"],"tldr":"NRG-BR002 did not meet its progression endpoint for added metastasis-directed ablation in a selected breast-cancer population. The planned phase 3 portion did not proceed.","summary":"The 2026 report analysed 125 eligible participants among 129 enrolled. Most had HR-positive, HER2-negative disease; 93 percent of ablation was SBRT. The study compared first-line systemic treatment alone with the same approach plus treatment of visible metastases.\n\nProgression-free survival was measured from randomisation. The trial did not show a statistically significant progression-free or overall-survival improvement and did not proceed to phase 3. The captured registry lists completed status. These findings do not erase palliation or establish the effect in every breast subtype or other disease setting.","status":"negative","asOf":"2026-11-09","links":[{"label":"ClinicalTrials.gov registry","url":"https://clinicaltrials.gov/study/NCT02364557"},{"label":"Primary 2026 report","url":"https://pubmed.ncbi.nlm.nih.gov/42842849/"}],"tags":["education-audit","local-treatment"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":["sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nrg-br002-jco-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02364557","phase":"2/3","setting":"Breast cancer with no more than four metastases, controlled primary and no progression on up to twelve months of first-line systemic therapy: standard care with or without metastasis-directed SBRT/surgery","sponsor":"NRG Oncology","result":"Progression-free survival hazard ratio 0.92, 95 percent confidence interval 0.57 to 1.47; overall-survival hazard ratio 1.07, interval 0.60 to 1.89.","started":"2014-12-24","startedType":"actual","yearReported":2026,"enrolled":129,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival from randomisation, eligible 2026 analysis","primary":true,"unit":"months","arms":[{"name":"Systemic therapy plus ablation","value":19.5,"note":"The 2026 eligible analysis; confidence interval for the hazard ratio is 95 percent."},{"name":"Systemic therapy without ablation","value":23}],"hr":0.92,"ci":[0.57,1.47],"p":"0.42","source":"https://pubmed.ncbi.nlm.nih.gov/42842849/"}]},"route":"/trials/nrg-br002/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"technology":[{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"paper":[{"id":"paper-nrg-br002-jco-2026","kind":"paper","name":"NRG-BR002: metastasis-directed ablation during first-line therapy for limited metastatic breast cancer","route":"/key-papers/paper-nrg-br002-jco-2026/"}],"person":[{"id":"eleftherios-mamounas","kind":"person","name":"Eleftherios P. Mamounas","route":"/people/eleftherios-mamounas/"}]}}